Skip to content
Home/Companies/MedTech/Promimic
Promimic

Promimic

MedTech·Sweden·Active·13yr hold
Entry
2013
Hold
13yr
Status
Active

Who owns Promimic?

Promimic is a Swedish MedTech company, currently owned by Rosetta Capital since 2013.

Hand-verified · updated 2026-06-30

Open JSON · CC-BY
Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorMedTech
StatusActive
Websitepromimic.com

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Akinion Pharmaceuticals
Active
PharmaSweden· 2013
Aprea Therapeutics
Exited 2019
BiotechSweden· 2013
Axelar
Active
BiotechSweden· 2013
Biosergen
Exited 2021
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Dilafor
Active
BiotechSweden· 2013

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Promimic?

Promimic is currently owned by Rosetta Capital, through Rosetta Capital IV, since 2013.

When did Rosetta Capital acquire Promimic?

Rosetta Capital acquired Promimic in 2013.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue